Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.

ABSTRACT:

Background & aims

Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated with chronic liver disease in patients undergoing planned invasive procedures. This post-hoc analysis assessed the magnitude of platelet count change based on the integrated per-protocol population from 2 similar phase III multicentre, randomised, double-blind, placebo-controlled trials.

Methods

Adults with chronic liver disease-induced thrombocytopaenia and platelet count <50 (× 10⁹/L) received lusutrombopag 3 mg or placebo ≤7 days before invasive procedure scheduled 9-14 days after randomisation. Platelet trans

SUBMITTER: Brown RS 

PROVIDER: S-EPMC7887643 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature